- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Amcenestrant Demonstrates Intriguing Activity in Postmenopausal Advanced ER+ Breast Cancer
December 11th 2020, 12:09am
San Antonio Breast Cancer Symposium
December 10, 2020 - Amcenestrant elicited antitumor activity in heavily pretreated, postmenopausal women with advanced or metastatic estrogen receptor–positive breast cancer.
Neoadjuvant Atezolizumab/Chemo Improves Outcomes Without Impacting Day-to-Day Function or HRQoL in Early TNBC
December 10th 2020, 11:22pm
San Antonio Breast Cancer Symposium
December 10, 2020 - The addition of neoadjuvant atezolizumab to nab-paclitaxel followed by doxorubicin plus cyclophosphamide was found to improve pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden to patients.
Dr. Tolaney on the Safety Profile of SAR439859 in ER+/HER2- Metastatic Breast Cancer
December 10th 2020, 11:21pm
San Antonio Breast Cancer Symposium
Sara M. Tolaney, MD, MPH, discusses the safety profile of SAR439859 in estrogen receptor–positive, HER2-negative metastatic breast cancer.
Dr. Tripathy on Updated Results of the MONALEESA-7 Trial in HR+/HER2- Breast Cancer
December 10th 2020, 11:15pm
San Antonio Breast Cancer Symposium
Debu Tripathy, MD, discusses updated results of the phase 3 MONALEESA-7 trial in hormone receptor–positive, HER2-negative breast cancer.
Sacituzumab Govitecan Induces Clinical Benefit in Metastatic TNBC, Irrespective of Trop-2 Expression
December 10th 2020, 10:28pm
San Antonio Breast Cancer Symposium
December 10, 2020 - The antibody-drug conjugate sacituzumab govitecan was found to induce clinical benefit over physician’s choice of therapy in patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression; however, greater efficacy was observed in those who had a medium or high Trop-2 score.
Efficacy Analysis for Frontline Combination Therapy With Pembrolizumab Indicates Benefit in TNBC, Regardless of Chemotherapy Choice
December 10th 2020, 10:24pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Frontline pembrolizumab plus chemotherapy for advanced triple-negative breast cancer demonstrated efficacy across key patient subgroups, including those with PD-L1 expression by combined positive score.
Ipatasertib/Paclitaxel Fails to Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC
December 10th 2020, 10:24pm
San Antonio Breast Cancer Symposium
December 10, 2020 — The combination of ipatasertib and paclitaxel failed to show a significant improvement in progression-free survival vs placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.
CTC Count Possible Biomarker for Using HER2-Directed Therapy in MBC
December 10th 2020, 8:14pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Favorable outcomes after treatment with the HER2-directed lapatinib were indicated by early declines in circulating tumor cell counts in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.
Neratinib Leads to Fewer Deaths, CNS Benefit, Potential OS Improvement in Early-Stage HER2+ Breast Cancer
December 10th 2020, 8:14pm
San Antonio Breast Cancer Symposium
December 10, 2020 - At 8 years of follow up, fewer deaths and improved cumulative incidence of central nervous system recurrences were reported with adjuvant neratinib compared with placebo in patients with early-stage HER2-positive breast cancer after trastuzumab-based therapy, according to updated results of the phase 3 ExteNET trial.
Alpelisib/Letrozole Retains Efficacy in PIK3CA-Mutant HR+ Advanced Breast Cancer Post-CDK4/6 Inhibition/Fulvestrant
December 10th 2020, 8:12pm
San Antonio Breast Cancer Symposium
The combination of alpelisib and letrozole sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant hormone receptor–positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant.
Pregnancy May Be Difficult for Breast Cancer Survivors, But Often Produces Healthy Babies with No Impact on Long-Term Survival
December 10th 2020, 8:02pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.
Oral Paclitaxel-Encequidar Elicits Responses in Radiation-Associated Breast Angiosarcoma
December 10th 2020, 7:04pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Oral paclitaxel in combination with encequidar may provide patients with radiation-associated breast angiosarcoma an effective treatment.
Greater Adherence to a Diet for Diabetes Reduction May Improve Survival for Breast Cancer
December 10th 2020, 7:00pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Women with stage 1 to 3 breast cancer who adhered to a diabetes risk reduction diet had improved survival versus those who did not follow this specific diet.
BluePrint Subtyping Could be a Predictor of Pertuzumab Benefit in Early Breast Cancer
December 10th 2020, 6:45pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay, showed a trend for greater benefit with adjuvant pertuzumab therapy, according to an exploratory analysis of the data from the APHINITY trial.
Ki-67 Can Be Used to Select Abemaciclib for Patients With High-Risk Early Breast Cancer
December 10th 2020, 6:40pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Treatment with abemaciclib in combination with endocrine therapy significantly reduced the risk of invasive disease recurrence or death in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer who had high Ki-67 tumors, suggesting that this feature can be used in conjunction with high-risk features to select patients for abemaciclib in the adjuvant setting.
Oral Paclitaxel-Encequidar Associated With Greater Efficacy, Lower Neuropathy Rates in mBC Compared to IV Paclitaxel Alone
December 10th 2020, 6:30pm
San Antonio Breast Cancer Symposium
December 10, 2020 — Oral paclitaxel and encequidar elicited lower rates of chemotherapy-induced peripheral neuropathy, as well as greater efficacy, in patients with metastatic breast cancer compared to intravenous paclitaxel.
Behavioral Interventions Reduce Depressive Symptoms in Young Breast Cancer Survivors
December 10th 2020, 5:18pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Mindfulness meditation and survivorship education classes reduced depressive symptoms in younger women treated for breast cancer.
Trastuzumab Deruxtecan Continues to Show Impressive Outcomes in HER2+ Metastatic Breast Cancer
December 10th 2020, 2:42pm
San Antonio Breast Cancer Symposium
December 10, 2020 - Fam-trastuzumab deruxtecan-nxki continued to showcase impressive signals of efficacy, including prolonged, durable responses and overall survival rates, as well as a tolerable safety profile in patients with HER2-positive metastatic breast cancer.
Ribociclib Continues to Showcase Significant Survival Benefit in HR+/HER2– Breast Cancer
December 10th 2020, 2:38pm
San Antonio Breast Cancer Symposium
December 10, 2020 — The addition of ribociclib to endocrine therapy continued to significantly improve overall survival and delay subsequent chemotherapy compared with placebo, irrespective of endocrine partner in patients with hormone receptor–positive, HER2-negative breast cancer.
Disease Recurrence Similar Between Tamoxifen, Anastrozole in Postmenopausal Women With DCIS
December 10th 2020, 12:48am
San Antonio Breast Cancer Symposium
December 9, 2020 - Treatment with tamoxifen versus anastrozole did not yield any significant difference in terms of disease recurrence in postmenopausal women with locally excised ductal carcinoma in situ but understanding associated toxicities can inform care decisions.